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Abstract
Background: During the course of a bacterial infection, the rapid identification of the causative
agent(s) is necessary for the determination of effective treatment options. We have developed a
method based on a modified broad-range PCR and an oligonucleotide microarray for the
simultaneous detection and identification of 12 bacterial pathogens at the species level. The broad-
range PCR primer mixture was designed using conserved regions of the bacterial topoisomerase
genes gyrB and parE. The primer design allowed the use of a novel DNA amplification method,
which produced labeled, single-stranded DNA suitable for microarray hybridization. The probes
on the microarray were designed from the alignments of species- or genus-specific variable regions
of the gyrB and parE genes flanked by the primers. We included mecA-specific primers and probes
in the same assay to indicate the presence of methicillin resistance in the bacterial species. The
feasibility of this assay in routine diagnostic testing was evaluated using 146 blood culture positive
and 40 blood culture negative samples.
Results: Comparison of our results with those of a conventional culture-based method revealed
a sensitivity of 96% (initial sensitivity of 82%) and specificity of 98%. Furthermore, only one cross-
reaction was observed upon investigating 102 culture isolates from 70 untargeted bacteria. The
total assay time was only three hours, including the time required for the DNA extraction, PCR
and microarray steps in sequence.
Conclusion:  The assay rapidly provides reliable data, which can guide optimal antimicrobial
treatment decisions in a timely manner.
Background
Conventional diagnosis of a bacterial infection mainly
relies on culture-based testing. These cultivations usually
yield diagnostic results in days or in some cases up to a
week after sampling. Furthermore, cultivation of bacteria
is not always successful under laboratory conditions. Such
failures may occur due to unsuitable culturing conditions
and methods for the bacterial species in question. Alterna-
tively, the particular patient under investigation may have
received antimicrobial therapy before sampling. Molecu-
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lar methods based on nucleic acid amplification and
hybridization aim to circumvent these problems and has-
ten diagnostic procedures. In such methods, the pathogen
is simultaneously detected and identified, which results in
more rapid diagnoses than those obtained by conven-
tional culturing methods and obviates the need for addi-
tional culture tests. Rapid diagnostics can also reduce the
use of antimicrobial agents in addition to allowing a faster
switch to the most optimum treatment, thus reducing
both side-effects and costs [1,2].
Microarrays allow the hybridization-based detection of
multiple targets in a single experiment. Arrays have mostly
been utilized in gene expression profiling. However, the
use of microarrays in microbial diagnostics has been
recently reviewed by Bodrossy and Sessitsch (2004) [3].
Roth and co-workers (2004) [4] described the diagnostic
oligonucleotide array targeting species-specific variable
regions of the topoisomerases genes gyrB and parE of res-
piratory bacterial pathogens. These authors used a broad-
range polymerase chain reaction (PCR) method, which is
based on the primers that recognize conserved sequences
of genes that encode essential molecules. The most com-
mon bacterial broad-range PCR methods use primers that
recognize conserved DNA sequences of bacterial genes
that encode ribosomal RNA (rRNA 16S or 23S). However,
resolution problems at the genus and/or species level
occur when distinguishing between closely related bacte-
rial species solely by their conserved 16S rDNA sequences.
Moreover, the sequencing of the whole 16S rRNA gene is
recommended for reliable microbial speciation [5]. In
comparison, the gyrB gene discriminates between related
bacterial species more precisely than the 16S rRNA gene,
which makes it a more suitable gene for such species iden-
tification [6,7].
In addition to identifying the causative pathogen of the
infection, the rapid identification of antimicrobial resist-
ance markers can further guide and, if necessary, re-direct
the appropriate treatment. Methicillin resistant Staphyloco-
ccus aureus (MRSA) is one of the common pathogens
responsible for nosocomial infections. Furthermore,
among coagulase-negative staphylococci (CNS), methicil-
lin resistance is prevalent [8]. Methicillin resistance in Sta-
phylococcus species arises principally by the acquisition of
a large genetic element, the staphylococcal cassette chro-
mosome, SCCmec [9]. The SCCmec carries the mecA gene,
which encodes penicillin binding protein PBP2a, the
main causal factor of methicillin resistance. Different
types of SCCmec cassettes and their variants have been
identified [10,11]. The current methods for MRSA detec-
tion are based on either the phenotypic expression such as
oxacillin resistance, or genotypic characterization.
For this study, we used modified broad-range PCR prim-
ers that originate from the conserved regions of genes that
encode the topoisomerases together with specific oligonu-
cleotide probes located at hyper-variable regions flanked
by the primers. Using these primers and probes, single or
even multiple infection-causing bacteria could be simulta-
neously detected and identified. The bacterial pathogen
panel of the assay covered the following species: Acineto-
bacter baumannii, Enterococcus faecalis, Enterococcus faecium,
Haemophilus influenzae, Klebsiella pneumoniae,  Listeria
monocytogenes, Neisseria meningitidis, Staphylococcus aureus,
Staphylococcus epidermidis, Streptococcus agalactiae, Strepto-
coccus pneumoniae, Streptococcus pyogenes and selected CNS
species. These bacteria are examples of highly virulent,
potentially multi-antimicrobial resistant or the most com-
mon etiologic agents associated with various life-threaten-
ing conditions. Such conditions include: sepsis, infective
endocarditis and central nervous system infection. All
these conditions necessitate rapid and accurate diagnos-
tics to improve the chances of a positive outcome for the
patient. We used the ArrayTube™ as a microarray platform
for the probes. The ArrayTube™ has been demonstrated to
detect and identify bacterial pathogens with a high degree
of sensitivity [12-14], differentiate between various patho-
types of the same bacterial species [15] and to be capable
of detecting antimicrobial resistance genes [16] from an
isolated DNA sample. Furthermore, by including specific
primers and probes for the mecA methicillin resistance
gene in the same assay, we were able to associate the mecA
gene with a particular Staphylococcus species present in the
sample. The combination of broad-range PCR and array-
based methods provided a sensitive and specific approach
for detecting and identifying bacterial pathogens along
with finding possible resistance markers.
Results
Assay design
First, we re-designed and modified the bacterial broad-
range gyrB/parE primers [4] by using inosines to reduce
the level of degeneration. These modifications also facili-
tated the use of a novel PCR method for the assay (PCR
program described in Materials and Methods). The PCR
method had two distinct phases: a three-step PCR phase
that exponentially produced dsDNA, followed by a two-
step PCR phase that took place under two different condi-
tions and which produced ssDNA in a linear manner. The
method is based on partly overlapping annealing temper-
atures of the forward and reverse primers. After the PCR
step, amplicons were directly, without any denaturation
step, used in hybridization, due to the production of
ssDNA during the second PCR phase. This avoided the
problems resulting from suboptimal or unreliable dena-
turation associated with standard PCR methods. The
effectiveness of the re-designed gyrB/parE primers and the
production of ssDNA during the PCR step were assessed
using DNA extracts of various bacterial species. Figure 1
shows the production of ssDNA and the same or even
improved sensitivity for bacteria included in the assay
panel.BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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When designing the microarray probes for A. baumannii,
E. faecalis, E. faecium,  H. influenzae, K. pneumoniae,  L.
monocytogenes, N. meningitidis, S. aureus, S. epidermidis, S.
agalactiae, S. pneumoniae, S. pyogenes, and the selected CNS
species, we used the gyrB and parE sequences of these bac-
teria together with those of other clinically relevant bacte-
ria. The sequence alignments were used to maximize the
specific hybridization of the consensus sequences of the
targeted bacteria, while minimizing the cross-hybridiza-
tion of sequences of any non-targeted bacteria. Various in
silico parameters were used in the design process to assess
the accuracy of the oligonucleotide probes. Annealing
potential was predicted by calculating the thermodynamic
factors, whereas sequence specificity was evaluated by
sequence comparisons and homologue searches of the
EBI and NCBI databases using the BLAST algorithm. The
oligonucleotide probes for the final microarray layout
(Table 1) were chosen from a set of oligonucleotide
probes tested in the laboratory.
We added an option for molecular identification of
methicillin resistant Staphylococcus  species by including
the methicillin resistance gene mecA  in the assay. The
identification was based on multiplex PCR amplification
of the gyrB/parE and mecA gene fragments (Figure 2). We
then detected the presence of amplified S. aureus or S. epi-
dermidis DNA on the microarray by using species-specific
probes. The presence of coagulase negative staphylococcal
DNA other than that associated with S. epidermidis was
detected by genus-specific probes. The presence of the
~200 bp mecA PCR product was indicated by the mecA
probes. Thus, when the mecA association was correlated
with Staphylococcus aureus, Staphylococcus epidermidis, and
CNS detection, information about the methicillin resist-
ance of staphylococci was provided.
Analysis of Staphylococcus species on the array
Because the only probes covering multiple bacterial spe-
cies in the assay were the CNS probes, we investigated in
detail the coverage and specificity of our Staphylococcus
panel including probes for Staphylococcus aureus, Staphylo-
coccus epidermidis, and CNS species (Table 1). The CNS-
specific probes systematically detected specific staphylo-
coccal species including S. xylosus, S. haemolyticus, S. sapro-
phyticus, and S. lugdunensis. However, some other
clinically relevant Staphylococcal species, such as S. capitis,
S. cohnii, S. hominis, S. schleiferi, and S. warnerii were not
covered by the panel (Table 2).
S. epidermidis had specific probes for identification, which
functioned optimally. Similarly, the specific probes for S.
aureus functioned well, with the exception of one S. aureus
sample, which was not detected because only one of a
duplicate set of oligonucleotide probes was identified. In
the dataset, the mecA detection was associated with S. epi-
dermidis and S. aureus. Figure 3 shows the representative
hybridization result of MRSA clinical isolates, and illus-
trates the simultaneous detection of the gyrB and mecA tar-
gets. The hybridization results are displayed by the Prove-
it™ Advisor software, which provides the original and ana-
lyzed array images, analyzed data and the accompanied
statistics. The presence of S. epidermidis in a sample was
reported by the Prove-it™ Advisor software when S. epider-
midis specific probes were positive. According to the built-
in identification rules of the software, a CNS positive find-
ing would be reported when S. epidermidis specific probes
remained negative.
Evaluation of the specificity of the probes
To determine the wet-lab specificity of the oligonucle-
otide probes and any possible cross-hybridization that
might lead to false positive bacterial identification, the
sample material containing 102 clinical isolates of 70
untargeted bacteria (Table 3) were subjected to multiplex
gyrB/parE/mecA PCR and subsequent hybridization on the
microarray. In addition, specificity of dsDNA and ssDNA
amplification was verified by gel electrophoresis. The bac-
terial panel under test covered a large number of clinically
relevant bacterial species related to the targeted bacteria,
such as Streptococcus mitis, a close relative of pneumococ-
cus, and Klebsiella oxytoca and Klebsiella pneumoniae subsp.
ozeanae, close relatives of K. pneumoniae, and also bacteria
of normal flora, such as Corynebacterium and Stomatococcus
species. No significant cross-hybridization occurred
between any targets. Only one cross-hybridization led to
a false positive identification: Klebsiella pneumoniae subsp.
ozeanae was reported as Klebsiella pneumoniae subsp. pneu-
moniae.
Comparison of the amplification efficacy between the gyrB/ parE primer pairs of this study (lanes 1, 3, 5, and 7) and those  of Roth et al., (2004) [4] (lanes 2, 4, 6, and 8) Figure 1
Comparison of the amplification efficacy between 
the gyrB/parE primer pairs of this study (lanes 1, 3, 5, 
and 7) and those of Roth et al., (2004) [4] (lanes 2, 4, 
6, and 8). The production of ssDNA during the PCR pro-
gram are shown with the species of E. faecalis (lane 1 and 2), 
E. faecium (lane 3 and 4). K. pneumoniae (lane 5 and 6), and N. 
meningitidis (lane 7 and 8) by gel electrophoresis using a 2% 
agarose gel containing SYBR® Green II. The ssDNA ampli-
cons of gyrB/parE (200 bp) were detected using the primer 
pair of this study together with the dsDNA amplicons of 
gyrB/parE (300 bp).
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Table 1: Oligonucleotide probes included in the final microarray layout.
Targeted bacteria Sequence (5'->3') Length Tm (°C)
Acinetobacter baumannii AGTGTTTCAGATAATGGCC 19 47
AATTATTGTCACGATTCACGAGG 23 52
Enterococcus faecalis CTGGTATCCCAACAGTAGAAGTA (parE)2 3 5 3
Enterococcus faecium TATCACCGTTATTGACGACGGTC 23 55
GGATACCTGTAGATATCCAGGCA 23 55
Haemophilus influenzae GGCCATTGTTCCGATATTATCG 22 53
GTTCCGATATTATCGTGACAA 21 49
Klebsiella pneumoniae TACTGCAAAGATATCGTTGTCA 22 49
Listeria monocytogenes TACAATCGAAGCTGATAACAGCA 23 52
ACTGTTCGTGATAACGGACGTGG 23 57
GGTCGTCCAACAGTAGAAGT 20 52
Neisseria meningitidis AATCACGGTAACGATACACGC 21 52
Staphylococcus aureus CTGTCGAAGTTATTTTAACTGTTT 24 49
AATAGTATCGATGAAGCATTAGCTG 25 53
Staphylococcus epidermidis TAGTCATATTGAAGTTRTAATTGAG 25 48–49
CATTAGCAGGTTATGCTAGTCATA 24 52
CNS TCAACTTCAGAAAAAGGTTTACA 23 48
CGCCCAGCAGTTGAAGTTATCT 22 55
Streptococcus agalactiae TTACATTGAACCAGATAACTCTA 23 48BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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Evaluation of the assay using the blood culture dataset
We received a randomly obtained set of 186 blood culture
samples, including 146 blood culture positive and 40
blood culture negative samples, from the Department of
Bacteriology, HUSLAB (Finland) to compare the clinical
applicability of the assay with the standard methodology.
Samples were analyzed using the following workflow: a)
DNA was extracted using the easyMAG extraction device,
b) multiplex PCR amplification was performed in a stand-
ard thermal cycler and the success of amplification was
verified by gel electrophoresis, c) subsequent hybridiza-
tion was performed on the microarray, d) and finally the
analyses of the hybridization images and result reporting
were conducted using the Prove-it™ Advisor software. The
assay time for one sample or 24 samples, excluding time
required for sample preparation prior to DNA extraction,
was three or under four hours, respectively. The obtained
results were compared to the blood culture results
assessed by HUSLAB.
The DNA extraction and PCR controls included in each
test series were required to be negative for the acceptance
of a particular test series. Negative controls gave negative
hybridization results. However, two of these samples
could not be analyzed by software due to automatic grid-
ding problems. As a consequence, they were analyzed
manually. The target identification was interpreted using
the specific built-in rules and parameters of the Prove-it™
Advisor software. Briefly, all oligonucleotide probes for
the specific target including their duplicates were required
to be positive, with the exception of the CNS probes of
which two out of four probes were required for reporting
a positive finding. Furthermore, if the threshold limits
were not exceeded for the oligonucleotide probes being
measured, the obtained negative result was considered as
a true negative.
The identified bacteria are presented in Table 4. A total of
69 positive and 117 negative identifications were
obtained. Nine targets from the pathogen panel were
detected in the samples of which S. aureus, E. faecalis, and
S. epidermidis occurred with the highest incidences. The
other identified bacteria were K. pneumoniae, S. pneumo-
niae, S. pyogenes, E. faecium, S. agalactiae and CNS. Bacte-
rial species included in the pathogen panel, but not
present in the samples were A. baumannii, H. influenzae, L.
monocytogenes, and N. meningitidis. A total of 32 different
microbes were present in the blood culture positive sam-
ples, and none of these microbes caused false positive
identifications through cross-hybridization. The correct
negative result was achieved for numerous different path-
ogens including Bacillus sp., Escherichia coli, Enterobacter
cloacae,  Salmonella enterica subsp.  enterica, Streptococcus
sanguis, Streptococcus bovis, and Candida albicans (Table 4).
All of the 40 blood culture negative samples analyzed by
our assay were reported as negative.
When comparing our data with those of the blood culture
results, 17 discrepant results were observed, of which 15
were false negatives and two false positives. Six of the sam-
TGGAAGACCAGCTGTAGAGACAG 23 57
Streptococcus pneumoniae TGGTGATCGTATTGATGTAACTA (parE)2 3 5 0
Streptococcus pyogenes GTCCCGCCGTTGAAACAGTT 20 54
TTTTTACAGTCTTACACGCAGGT 23 52
GCAGGTTTTGCCTCTCATATTAAAGTCTT 29 57
mecA TGATTATGGCTCAGGTACTGC 21 52
TGGCTCAGGTACTGCTATCCA 21 54
ATTAGCACTTGTAAGCACACC 21 50
TACTGCTATCCACCCTCAAAC 21 52
If not otherwise stated, the presented sequence targets the gyrB gene.
Melting temperature (Tm, basic) is calculated using software available at http://www.basic.northwestern.edu/biotools/oligocalc.html.
Table 1: Oligonucleotide probes included in the final microarray layout. (Continued)BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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ples reported as false negatives contained S. agalactiae, S.
epidermidis, S. pneumoniae, E. faecalis, E. faecium, and S.
aureus as a causative agent. In these cases, the strict detec-
tion rules caused the final outcome to be below the level
required for positive identification. These six false nega-
tives were caused by either one completely missing or one
low quality duplicated probe, giving results that were
insufficient to meet the strict positive identification crite-
ria. Therefore these samples were reported as negative
findings by the Prove-it™ Advisor, although other dupli-
cates and probes were detected. We noticed that by using
less strict identification rules, these samples were identi-
fied correctly. Thus, these samples were considered to be
true positives when calculating the final specificity and
sensitivity values of the assay.
The other nine samples reported negative by the the
Prove-it™ Advisor were: S. pyogenes, S. aureus, S. epider-
midis, and six CNS samples. We sequenced the CNS sam-
ples using the 16S rRNA gene. Sequencing revealed that
these unidentified CNS samples contained S. pasteuri, S.
capitis and S. hominis (four samples). The mecA gene was
identified in two of the CNS samples. The two positive
mecA findings were associated with S. capitis and S. hom-
inis. None of the species in the six CNS samples was cov-
ered by the CNS probes of the assay panel (Table 2), thus
these samples were considered to be true negatives. The
reasons for the remaining three false negative samples (S.
pyogenes,  S. aureus,  S. epidermidis) remained undeter-
mined. The samples were not amplified by the 16s rRNA
PCR, suggesting that they could have contained PCR
inhibitors or degraded DNA.
Two false positive results were observed due to the detec-
tion of the mecA gene marker associated with the non-sta-
phylococcus causative agent S. pneumoniae and E faecalis.
The causative agent was in line with the corresponding
blood culture result.
When the results of the assay were compared with the
identification provided by HUSLAB, a sensitivity of 82
percent and specificity of 98 percent were achieved. After
the alterations presented above were implemented, the
sensitivity increased to 96 percent while the specificity
remained at 98 percent (Table 5).
Discussion
Microarrays are widely used in gene expression and geno-
typing applications in research settings but their use in
diagnostics is still rare. Nevertheless, microarray technol-
ogy and DNA-based approaches are believed to have great
clinical potential in the field of infectious diseases [17]. In
this study, we described a combined PCR- and microar-
ray-based assay for the rapid and reliable detection of A.
baumannii, E. faecalis, E. faecium, H. influenzae, K. pneumo-
niae, L. monocytogenes, N. meningitidis, S. aureus, S. epider-
Multiplex amplification of gyrB and mecA visualized by electropherograms (Agilent Technologies 2100 Bioanalyzer) in two  MRSA clinical isolates Figure 2
Multiplex amplification of gyrB and mecA visualized by electropherograms (Agilent Technologies 2100 Bioana-
lyzer) in two MRSA clinical isolates. X-axis presents time (s) and Y-axis presents the amount of fluorescence (FU).BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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midis, S. agalactiae, S. pneumoniae, S. pyogenes and selected
CNS (non-S. epidermidis) species.
In this study, we introduced a novel multiplex-PCR
method that first produces dsDNA exponentially, after
which ssDNA is produced in a linear manner. During the
linear phase, the high annealing temperature allows only
the reverse primer to function due to the Tm difference
between forward and reverse primers. Thus the whole PCR
procedure can be conveniently performed in a single mul-
tiplex PCR amplification reaction without manual
involvement. In our method, sufficient quantities of
ssDNA are produced during the PCR reaction. Conse-
quently, the conventional methods such as alkali or heat
treatment, or asymmetric PCR are rendered unnecessary
for generating a single stranded target for microarray
hybridization [18,19]. Our method, therefore, enables a
rapid protocol for assay as hybridization can be per-
formed immediately after the PCR step. A similar type of
PCR method has been developed by Zhu et al. (2007)
[20]. These authors used forward primers tagged with an
unrelated universal sequence at the 5' end to create the
necessary Tm difference between the forward and reverse
primer. In contrast to the method of Zhu et al. (2007) [20]
the temperature difference in our method is achieved by
target-specific primers that enable rapid PCR cycling. In
this study, we used our method for the multiplex amplifi-
cation of the gyrB and mecA genes.
Table 2: The species coverage of Staphylococcus probe panel.
Phenotypic identification Number of strains Positive identification on microarray Negative identification on microarray
S. capitis 1 1
S. cohnii 1 1
S. haemolyticus 11
S. hominis 2 2
S. ludgunensis 22
S. saprophyticus 22
S. schleiferi 1 1
S. warnerii 2 2
S. xylosus 22
TOTAL 14 7 7
S. epidermidis 22
S. epidermidis + mecA 22
TOTAL 4 4 0
S. aureus 5 4 1 (2/4 probes identified)
S. aureus + mecA 33
S. intermedius 1 1
TOTAL 9 7 2BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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The gyrB gene region has been shown to be capable of dis-
crimination when identifying closely related bacterial spe-
cies [6,7]. When the specificity of our assay was evaluated
using nucleic acid from 70 different untargeted bacteria,
only one cross-reaction was observed: Klebsiella pneumo-
niae subsp. ozeanae was reported as Klebsiella pneumoniae
subsp. pneumoniae. In addition to the gyrB gene, the 16S
rRNA gene has been used in bacterial speciation, partly
due to the large number of microbial 16S rDNA sequences
available in the public databases [5,21]. In this study, the
16S rRNA gene and the corresponding public databases
were used to study objectively any discrepancies in bacte-
rial identification between the compared methods.
Despite the selected gene, designing discriminating
probes between closely related species can be demanding.
Setting the appropriate threshold values and making iden-
tification rules for target detection are specific challenges,
which can be overcome by the means of bioinformatics.
In our study, the final identification of a bacterial patho-
gen was based on one to three different oligonucleotides
on the microarray. All these were spotted as duplicates
and all of which, with the exception of CNS, were required
to pass threshold values set for their positive identifica-
tion. When more pathogens are included on the array, the
designing of the probes, the setting of threshold values
[22], and formulation of identification rules will require
Detection of methicillin resistant Staphylococcus aureus (MRSA) using the Prove-it™ Advisor software Figure 3
Detection of methicillin resistant Staphylococcus aureus (MRSA) using the Prove-it™ Advisor software. The 
original array image illustrates the positive hybridization of Staphylococcus aureus and mecA targets. The accompanied statistics 
are also visualized. In the processed image, yellow spots denote the identified target oligonucleotides and green spots the iden-
tified position control oligonucleotides. The unmarked visible spots are not included in the final array layout.BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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Table 3: Results of specificity testing using clinical isolates and reference strains of untargeted bacteria.
Phenotypic identification No of strains Negative identification on 
microarray
Positive identification on 
microarray
Actinobacillus actinomycetemcomitans 22
Actinomyces sp 1 1
Aerococcus viridans 11
Aeromonas hydrophila 11
Aeromonas sobria 22
Alcaligenes xylosox 11
Arcanobacterium haemolyticum 22
Bacillus cereus 22
Bacillus sp 2 2
Bacteroides fragilis group 2 2
Bacteroides ureolyticus 11
Campylobacter fetus 22
Campylobacter coli 11
Campylobacter jejuni 22
Capnocytophaga canimorsus 11
Citrobacter diversus 11
Clostridium clostridiumforme 11
Clostridium perfringens 11
Clostrium sp 2 2
Corynebacterium jeikeium 22
Corynebacterium sp 2 2
Desulfovibrio sp 2 2
Diphtheroid 22
Enterobacter aerogenes 11
Enterobacter cloacae 22
Enterobacter hormaechei 11
Enterobacter sp 1 1
Enterococcus avium 22BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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Enterococcus casseliflavus 11
Eubacterium sp 1 1
Fusobacterium nucleatum 11
Hafnia alvei 22
Klebsiella oxytoca 22
Klebsiella ozeanae 11
Lactobacillus sp 1 1
Lactococcus sp 1 1
Leuconostoc sp 2 2
Micromonas micros 11
Moraxella catarrhalis 22
Moraxella sp 2 2
Morganella morganii 22
Pantoea agglomerans 11
Pantoea sp 1 1
Peptostreptococcus sp 1 1
Porphyromonas gingivalis 11
Prevotella sp 1 1
Propionibacterium acnes 22
Proteus vulgaris 11
Pseudomonas fluorecens 11
Pseudomonas fluorecens/putida 11
Pseudomonas oryzihabitans 11
Pseudomonas stutzeri 22
Rothia dentacariosa 11
Salmonella enterica subsp. enterica 22
Serratia liquifaciens 11
Serratia marcescens 22
Sphingomonas paucimobilis 11
Stenotrophomonas maltophilia 22
Table 3: Results of specificity testing using clinical isolates and reference strains of untargeted bacteria. (Continued)BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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Stomatococcus mucilaginosus 11
Stomatococcus sp 1 1
Streptococcus anginosus 22
Streptococcus bovis 22
Streptococcus dysgalactiae subsp. equisimilis 11
Streptococcus equisimilis 11
Streptococcus group G 2 2
Streptococcus mitis 22
Streptococcus sanguis 22
Streptococcus sp 1 1
Streptococcus viridans 22
Yersinia pseudotuberculosis 11
TOTAL 102 101 1
Table 3: Results of specificity testing using clinical isolates and reference strains of untargeted bacteria. (Continued)
Table 4: Pathogens identified from the blood culture samples using PCR- and microarray-based analysis.
Correct positive identification of the bacteria Number Correct negative identification Number
Staphylococcus aureus 24 Bacillus sp 2
Enterococcus faecalis 9 Bacteroides fragilis group 2
Staphylococcus epidermidis +mecA 8 Candida albicans 4
Klebsiella pneumoniae 7 Diphtheroid 1
Streptococcus pneumoniae 6 Enterobacter cloacae 1
Streptococcus pyogenes 6 Enterococcus casseliflavus 1
Enterococcus faecium 4 Enterococcus sp 4
CNS (Staphylococcus haemolyticus)1 Escherichia coli 19
CNS + mecA (S. haemolyticus)1 Escherichia coli, Streptococcus viridans 2
Streptococcus agalactiae 1 Fusobacterium necrophorum 3
Fusobacterium nucleatum, Micromonas micros 1
Correct positive identification of the bacteria but an additional 
mecA marker identified
Klebsiella oxytoca 4
Streptococcus pneumoniae + mecA 1 Micrococcus sp 1BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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Enterococcus faecalis + mecA 1 Propionibacter sp 2
Pseudomonas aeruginosa 3
Pseudomonas-like gram- rod 1
Salmonella Enteritidis 3
Salmonella Paratyphi A 1
Stenotrophomonas maltophilia 1
Streptococcus betahemolytic group C 1
Streptococcus bovis 1
Streptococcus sanguis
(co-infection with K. pneumoniae)
Streptococcus viridans 4
Blood culture negative samples 40
False negative identification*
CNS 6 (0)
Staphylococcus aureus 2 (1)
Staphylococcus epidermidis 2 (1)
Streptococcus pyogenes 1 (1)
Streptococcus agalactiae 1 (0)
Streptococcus pneumoniae 1 (0)
Enterococcus faecalis 1 (0)
Enterococcus faecium 1 (0)
* The figures obtained after post hoc adjustments are presented in parentheses
Table 4: Pathogens identified from the blood culture samples using PCR- and microarray-based analysis. (Continued)
intensive testing. The testing procedure can be enhanced
by automated data analysis, which provides objective and
reproducible interpretation of the results. In our study, the
Prove-it™ Advisor software generated data analysis for
reporting and allowed effective data management and
tracking.
We evaluated the assay by comparing its results with those
of sepsis diagnostics, although other applications using
specimens from normally sterile site of the body are feasi-
ble as well. Our sample material consisted of 186 blood
culture samples and causative agents were identified orig-
inally in 69 of these samples. These positives corre-
sponded to nine of the targets on the assay pathogen
panel. However, some of the targets in the pathogen
panel, A. baumannii, H. influenzae, L. monocytogenes, and
N. meningitidis, were not present in any of the samples and
no false identifications of these bacteria were made. When
comparing these data with those of the blood culture
results, discrepancies were observed due to the limited
numbers of CNS probes on the panel, or for unknown rea-
sons. The CNS probes on the panel were selected to cover
the two most clinically prevalent CNS species S. haemolyti-
cus and S. saprophyticus, and the most virulent species S.
lugdunensis. If more CNS species were needed to be cov-
ered by the assay, their respective probes could beBMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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designed and added to the CNS probe panel [23]. Such
species could be S. pasteuri, S. capitis and S. hominis all
three of which were present in the blood cultures analyzed
in our study.
We encountered some challenges with reconciling the
microarray image analyses data and building optimal
detection rules for the precise identification of all the
pathogens. These specific problems are illustrated by
missing or suboptimal duplicates causing false negative
identifications. The microarray image and data analysis
present commonly acknowledged challenges, especially
when the microarray data quality is not optimal. For
instance, the distinction between the actual spots and arti-
facts on the array, or the gridding of the image can be
problematic [24]. These challenges in automated image
and data analyses together with result reporting could be
a reason for the current lack of available microarray-based
diagnostics. In this study, a few microarray images and
results were interpreted manually to overcome the techni-
cal problems encountered. Of course, this would not be
appropriate for a diagnostic assay, for which such post hoc
adjustments could not be made.
In general, the adjusted results were in line with the con-
ventional blood culturing method, regarded as a gold
standard in sepsis diagnostics. Our data had a specificity
of 98 percent and sensitivity of 96 percent (initial sensitiv-
ity of 82 percent). Similar results namely: a specificity of
100 percent for the genus level and 97 percent for the spe-
cies level using reference strains and clinical isolates were
reported by a comparable method [21].
Simultaneous early detection of antimicrobial resistance
markers and the causative pathogen of an infection in a
clinical setting can direct the antimicrobial treatment opti-
mally [2]. In our study, we included the methicillin resist-
ance gene mecA in the assay. As a consequence, the mecA
findings were associated with the positive findings of S.
epidermidis or other CNS bacteria. Two samples had non-
staphylococci bacteria and these mecA findings were later
indicated as positive for CNS (data not shown). In Fin-
land, the prevalence of MRSA in bloodstream infections is
low [25]. Therefore, no MRSA samples were included in
the clinical samples. For this reason, our data demonstrate
the combined detection of S. aureus and the mecA gene
fragment with the clinical isolate of MRSA (Figure 3).
Conclusion
Genotypic characterization of bacteria is advantageous
when compared to phenotypic methods. The latter
require a prolonged cultivation period for the suspected
bacteria and pure bacterial cultures for various biochemi-
cal assays. The accurate detection of multiple pathogens
and resistance markers simultaneously reduces the time
needed to start effective antimicrobial treatment. We con-
clude that broad-range PCR amplification with subse-
quent hybridization on a microarray is a rapid diagnostic
tool in identifying causative agents of bacterial infections
in various specimens from normally sterile site of the
body or non-cultured samples. In this study, we presented
proof-of-concept for one combination of bacterial probes
but depending on the clinical application, the assay could
be modified to cover different species profiles.
Methods
Samples
Clinical isolates and reference strains for cross-hybridization studies
A total of 102 clinical isolates and reference strains of var-
ious bacteria from American Type Culture Collection
(ATCC, VA), Deutsche Sammlung von Mikroorganismen
und Zellkulturen (DSMZ, Germany), or Helsinki Univer-
sity Central Hospital Laboratory (HUSLAB, Finland) were
used for the cross-hybridization comparisons. Bacteria
were grown in cystine lactose-electrolyte-deficient
(CLED), blood, or chocolate agar plates. Culturing was
performed under aerobic or anaerobic conditions
depending on the bacterial species. All strains were incu-
bated at 37°C for at least for 24 hours.
Clinical isolates and reference strains of Staphyloccus species
The Staphylococcus samples comprised ATCC strains and
clinical isolates that were characterized by conventional
methods. A total of 18 CNS samples including S. capitis
(ATCC27840),  S. cohnii (ATCC29972),  S. haemolyticus
(one clinical isolate), S. hominis (ATCC25615,
ATCC27844),  S. lugdunensis (two clinical isolates), S.
saprophyticus (two clinical isolates), S. warnerii (one clini-
cal isolate, ATCC25614), S. xylosus (ATCC29971,
ATCC35033), S. schleiferi (DSMZ4809), and S. epidermidis
(two clinical isolates, ATCC14990, ATCC49134) were
obtained for testing. Coagulase-positive staphylococcus S.
intermedius (ATCC29663), S. aureus (four clinical isolates,
ATCC29213), and MRSA were also included (three clini-
cal isolates).
Clinical isolates and reference strains of Staphylococcus
species were grown using the standard methodologies.
Briefly, lyophilized bacterial strains were diluted by Luria-
Bertani (LB) or tryptic soy broth. After dilution, nearly all
bacterial species were grown on blood agar plates. The
three exceptions were S. epidermidis ATCC14990 and S.
capitis ATCC27840 that were both grown on tryptic soy
agar plates, and S. epidermidis ATCC49134 that was grown
on a nutrient agar plate. Culturing was performed under
aerobic conditions with the exception of S. saprophyticus,
which was grown under anaerobic conditions. All strains
were incubated at 37°C for least 24 hours.
Blood cultures
Blood samples were drawn into aerobic and anaerobic
blood culture bottles (BacT/Alert®, bioMérieux, France)BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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and were incubated in the blood culturing equipment
BacT/ALERT 3 D (bioMérieux) for up to 5 or 6 days, at
which time they were reported as negative when no sign
of micro-organism growth was detected. If during the cul-
tivation period possible growth was observed by the
blood culturing instrument, it was identified and reported
according to CLSI guidelines http://www.clsi.org in the
Department of Bacteriology, HUSLAB (Finland). The cul-
tivation took 1–3 days, with a further 1–2 days culture
needed for the identification of pathogen from a positive
blood culture. In total, 186 blood cultures were collected
between May 2007 and June 2007. These were used as ref-
erences to evaluate the performance and feasibility of the
assay with that of standard routine diagnostic testing. Of
these, 146 were blood culture positive and 40 were blood
culture negative.
Oxacillin resistance
The susceptibility to oxacillin of the staphylococcal spe-
cies was determined by disc diffusion according to CLSI
guidelines, using Mueller-Hinton II agar base (cat no
212257, Becton, Dickinson and Company, USA) and
antibiotic discs (Oxoid, UK), incubated at +35°C. Mini-
mal inhibitory concentrations (MIC) values for oxacillin
were determined by E-tests (Biodisk, Sweden) on Mueller-
Hinton agar supplemented with 4 percent NaCl, and incu-
bated at +30°C.
Dna Extraction
The extraction of DNA from clinical isolates and reference
strains was carried out as follows: one bacterial colony
was picked from the plate and suspended in 100 μl of PBS.
After centrifugation (at 3000 rpm, for 3 minutes), the
supernatant was discarded and the pellet was suspended
in 100 μl of TE. Two heating steps of 95°C for five min-
utes were performed sequentially with a 2 minutes cool-
ing step between them. Finally, the solution was
centrifuged (at 13 000 rpm, for 10 minutes) and the
supernatant containing DNA was collected. In the case of
the blood culture samples, 100 μl of the samples were col-
lected for DNA extraction. The DNA was extracted using
an automated nucleic acid extraction instrument Nucli-
sens®easyMAG™ (bioMérieux, France) according to the
manufacturer's protocol (Generic 1.0.6). The eluation vol-
ume was 55 μl. A negative control, i.e., sterile water was
included in each test series.
Dna Amplification and Labelling
The broad-range PCR primers gBF (5'-CGICCIGGKATG-
TAYATHGG-3') and gBR (5'-RMICCWACICCRTGYAGIC-
CICC-3') were modified from primers introduced by Roth
and colleagues (2004) [4]. We reduced the number of
degenerated regions in primers by using inosines. The
primers amplified a ~300 bp region of the bacterial gyrB
and  parE  genes. In addition, specific primers for mecA
gene, mecAR (5'-TTACTCATGCCATACATAAATGGATA-
GACG-3') and mecAF (5'-AATACAATCGCACATACAT-
TAATA-3'), were designed. To enhance S. aureus
amplification SaurF (5'-AGACCTGGTATGTATATTGG-3')
and SaurR (5'-CCAACACCATGTAAACCACC-3') primers
were further designed. All the reverse primers were bioti-
nylated at their respective 5'-end.
The PCR reaction mixture contained 1 μM of gBF primer
mixture (Metabion, Germany), 1 μM of biotin-labeled
gBR primer mixture (Metabion, Germany), 0.165 μM of
SaurF primer (Metabion, Germany), 0.165 μM of biotin-
labeled SaurR primer (Metabion, Germany), 0.25 μM of
mecAF primer (Metabion, Germany), 0.25 μM biotin-
labeled mecAR primer (Metabion, Germany), 1× Hot Start
Taq® PCR buffer (Qiagen, Germany), in which the final
concentration MgCl2was 2.0 mM, 300 μM of each of
dNTP (Finnzymes, Finland), 1.5 g/l BSA (EuroClone,
Italy), 0.125 U/μl Hot Start Taq® DNA polymerase (Qia-
gen, Germany), 1.5 μl of isolated DNA, and water to bring
the total volume to 15 μl. In the blood culture dataset, 1.5
μl of PCR control template was added in the reaction and
the equivalent amount of water was reduced. A negative
control, i.e., sterile water was included in each test series.
The PCR was performed using a Mastercycler® epgradient S
thermal cycler (Eppendorf, Germany). The following PCR
program was used: a denaturation step at 95°C for 15
minutes, 36 cycles of 10 seconds at 96°C, 35 seconds at
52°C, 10 seconds at 72°C, 5 cycles of 5 seconds at 96°C,
30 seconds at 65°C, 5 cycles of 5 seconds at 96°C and
Table 5: Comparison of the blood culture results with the PCR- and microarray-based analysis.
Positive identification on microarray Negative identification on microarray
Positive identification by conventional methods 73 3 Sensitivity 96%#
(89.0–98.6)*
Negative/positive identification by conventional 
methods
2 108 Specificity 98%
(93.6–99.5)*
* Calculations are conducted according to CLSI recommendations.
# Initial sensitivity of 82% was observed.BMC Microbiology 2009, 9:161 http://www.biomedcentral.com/1471-2180/9/161
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finally 30 seconds at 68°C. After the PCR, the success of
the amplification of double-stranded DNA and single-
stranded DNA was ascertained by gel electrophoresis
using a 2% agarose gel containing SYBR® Green II (Invitro-
gen, USA) or using Agilent BioAnalyzer (Agilent Technol-
ogies, USA).
Microarray Construction
The microarray platform was an ArrayTube™ (Clondiag,
Germany). The design of specific oligonucleotide probes
were carried out according to the principles and methods
described previously [4]. One to three different species-
specific oligonucleotide probes were selected for each tar-
get species. In total, 22 species-specific probes for 12 bac-
teria, 2 CNS-specific, and 4 mecA  resistance marker
specific probes (Metabion, Germany) were chosen for
spotting on the microarray (Table 1). All oligonucleotide
probes were spotted as duplicates on the array. Two differ-
ent oligonucleotides per spot were used for the mecA
probes. Position control oligonucleotides containing a
biotin label were attached to the array for verifying the
correct function of the hybridization reagents.
Hybridization and Scanning
The hybridization on microarray was performed as
described previously [12] with only slight modifications.
All incubation steps except that of the last precipitation
reaction were performed under continuous agitation of
550 rpm at 25°C. Briefly, a first a prewash with 500 μl of
water from 30 to 55°C for 5 to 10 minutes was done.
Hybridization at 55°C for 10 minutes, of 1 μl of the bioti-
nylated target and 99 μl hybridization buffer (250 mM
Na2HPO4, 4.5% SDS, 1 mM EDTA, 1×SSC) took place on
a microarray. When hybridization control oligonucle-
otides were included, they were added to the hybridiza-
tion buffer. After hybridization, the microarray was
washed in 500 μl of 0.2×SCC at 20°C for 5 minutes. Incu-
bation with 100 μl of blocking buffer (2% milk powder,
6×SSPE, 0.005% Triton-X100) was performed for 5 min-
utes at 30°C. Then 100 μl of 1:5000 dilution of streptavi-
din-conjugated horseradish peroxidase in PBS was
applied for 10 minutes at 30°C followed by a similar
washing step as described above. Finally, 100 μl of 3, 3', 5,
5'-tetramethylbenzidine (TMB) analog (Seramun Grün;
Seramun Diagnostica, Germany) was added for the pre-
cipitation reaction at 25°C for 10 minutes. Microarray
images were generated by ATR-01 Reader (Clondiag).
Data-Analysis
The array images were analyzed with the Prove-it™ Advisor
software (Mobidiag, Finland, http://www.mobid
iag.com). The software performed image analyses and
result reporting, including the identification of the bacte-
rial targets and the evaluation of the control probes. This
took place automatically without user involvement in
adjusting any of the parameters. The target identifications
were made by software using multiple parameters such as
signals from the probe oligonucleotides on the array.
These were interpreted using built-in rules and parameters
specific for each assay type. All the probes for a specific
bacterial target were required to be positive for that target
to be classified as positively identified, except for the CNS
probes of which only 2 of 4 specific oligonucleotides were
required to be positive. If both CNS and S. epidermidis
probes in the analyses were positive, only S. epidermidis
was reported due to its identification by species-specific
probes. The original array layout contained spots, which
were not included in the final probe panel. Microarray
data files have been deposited in NCBI's Gene Expression
Omnibus database and are accessible through GEO Series
accession number GSE17221.
Sequencing of CNS Samples
For sequencing of the CNS samples 16S_rRNA_F (5'-
AGAGTTTGATCYTGGYTYAG-3') [25] and 16S_rRNA_R
(5'CTTTACGCCCARTRAWTCCG-3') [26] were used as
reported earlier. The primers amplified a ~550 bp region
of the bacterial 16S rRNA genes. The PCR reaction mixture
contained F and R primer mixture at a final concentration
of 0.4 μM (Sigma, USA), 1× Hot Start Taq® PCR buffer
(Qiagen, Germany), in which the final concentration of
MgCl2 was 2.0 mM, 200 μM of each of dNTP (Finnzymes,
Finland), 0.8 g/l BSA (EuroClone, Italy), 0.05 U/μl Hot
Start Taq® DNA polymerase (Qiagen, Germany), 2.5 μl of
isolated DNA, and water to bring total volume to 25 μl.
The PCR was performed using a Mastercycler® epgradient S
thermal cycler (Eppendorf, Germany). The PCR program
was initialized by a 15 minute denaturation step at 95°C
followed 36 cycles of 30 seconds at 95°C, 30 seconds at
54°C, and 30 seconds at 72°C. The PCR program ended
with 10 minute step at 72°C. After the PCR, the success of
the amplification of dsDNA was verified by gel electro-
phoresis using 2% agarose gel containing ethidiumbro-
mide (Sigma, USA). The amplified PCR product was
purified using the QIAquick® PCR purification Kit (250)
(Qiagen, Germany) and a minimum of 50 ng of product
was mixed with either the forward or reverse primer (0.42
μM). Water was added to bring the total volume up to 12
μl. Sequencing was performed using cycle sequencing
with Big Dye Terminator kit (version 3.1) supplied by
Applied Biosystems (ABI, CA, USA) and the reactions
were run on ABI 3130xl capillary sequencer according to
the manufacturer's instructions.
Sequences were edited and analyzed with the Vector NTI
Advance™ (Invitrogen, USA) and BioEdit http://
www.mbio.ncsu.edu/BioEdit/bioedit.html programs
using the ClustalW alignment algorithm version 1.4 [27].
We used the BLAST algorithm [28] to search for homolo-
gous sequences in the European Bioinformatics database
and the National Center for Biotechnology Information
database http://www.ebi.ac.uk/Tools; blast.ncbi.nlm.nih.
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Statistical Analysis
We compared the results and calculated the sensitivity,
specificity, and confidence interval (CI) values according
to CLSI guidelines (EP12-A2, User protocol for evaluation
of qualitative test performance, http://www.clsi.org.
Briefly, these analyses were performed using the following
definitions: true-positive (TP), true-negative (TN), false-
negative (FN), and false-positive (FP). The sensitivity was
calculated as follows: TP/(TP+FN), and the specificity was
calculated as TN/(TN+FP).
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